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INTRODUCTION 
 
Hepatocellular carcinoma (HCC) is the most common form of malignant liver cancer and the 
third most common cause of cancer related mortality worldwide. The main reason for this is 
the lack of effective treatment approaches. Although the majority of HCC cases occur in Asia, 
it is as well a steadily increasing problem in the Western world, where it is primarily 
connected to severe alcoholic abuse and viral hepatitis.   
During the last several years there has been a progress in   understanding  the mechanisms 
underlying the development of liver cancer, including the  role of stem/progenitor cells in 
tumor initiation and progression. Transformed adult stem cells (ASC) in the liver, or cancer 
stem cells (CSC) appear to be the cause of cancer spread and relapse in some cases. 
Nevertheless, the changes that precede  the malignant transformation of liver cells are largely 
unknown, and there is very little information about the changes occurring before the onset  of 
tumor growth. A distinctive characteristic of this study is that I observed the appearance of 
liver cancer as a constant process,  evolving from the point of initiation to the terminal (lethal) 
stage, rather than dealing only with advanced tumors. This approach allowed us to build a 
timeframe of events, which accompany the transition from normal liver tissue to cancer and 
follow how  liver stem cells (SC) engage in this process. 
This work is part of a larger project, which  investigates the role of normal liver tissue SC in 
the formation of liver cancer. The ultimate goal is to get a more accurate idea about the 
distinctive features of the cell of origin in liver cancer, which would allow to develop more 
effective strategies for prevention of this deadly disease.  
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1.BACKGROUND 
1.1 Adult stem cell concept and liver maintenance 
1.1.1 Adult liver stem cell concept 
Adult stem cells (ASC) are generally defined as undifferentiated cells, which reside in certain 
tissue compartments and by differentiating along certain pathways, give rise to the major cell 
types, which compose a mature tissue. The most distinct characteristics of all stem cells are 
the ability of self-renewal and the capability to give raise to distinct cell types that make up a 
tissue. In case of the liver, the definition of stem cells is difficult, due to the self-renewing 
ability of mature biliary cells and hepatocytes (Santoni-Rugiu et al., 2005; Doulatov et al., 
2012 ) (Figure 1). 
 
 
Figure 1. Functional unit of the liver. A) Structure of the portal area B) Structure of the liver lobule (Duncan et 
al., 2009). 
1.1.2 Adult stem cells and liver maintenance 
The interplay between distinct cell populations in the liver underlies its ability to maintain the 
size of the organ during physiological cell turnover as well as different kinds of injuries. On 
the one hand, the liver consists of a great number of differentiated hepatocytes and 
cholangiocytes that are capable of self-replication, on the other hand, a small population of 
cells bearing stem cell properties are present, whose  role in liver homeostasis is not 
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completely clear, but the ability to produce liver tissue has been confirmed in transplantation 
studies (Schmelzer et al., 2007). 
 
It is hypothesized, that the role of these cell populations in liver regeneration and turnover 
might differ between rodent models and humans. Recent findings show, that in contrast to 
rodents, stem cells might play a role in human liver tissue turnover (Schmelzer et al., 2007). 
According to this model new hepatocytes arise from the stem cells in the portal area and 
migrate in the direction of the central vein (Fellous et al., 2009) (Figure 1, B). This model is 
known as the „Flowing Liver Model“ (Zajicek et al., 1985). However, most results suggest 
that the role of stem cells in maintenance of normal liver tissue is minor and the turnover is 
accomplished by the proliferation of hepatocytes and biliary cells (Malato et al., 2011).  
 
Stem cells seem to play a critical role in liver regeneration when the proliferation of 
differentiated cells is impaired due to intoxication or chronic injury, which results in the 
expansion of progenitor cells, a process known as the oval cell reaction (Okabe et al., 2009) 
(Figure 2) 
 
Figure 2. Liver stem/progenitor cell hierarchy. During chronic liver injury, a gradient of progenitor stem cells 
is generated by quiescent stem cells, residing in the biliary compartment. These cells expand into the 
parenchyma and regenerate the injured tissue (Duncan et al., 2009). 
 
1.1.3 Characteristics of adult liver stem/progenitor cells  
Most of the molecules that have been used to sort out the liver SC containing cell population 
are different adhesion molecules, which are expressed in the biliary epithelium. One of the 
surface markers that defines the liver stem cell population is the Epithelial Cell Adhesion 
Molecule (EPCAM), which is a characteristic for the biliary epithelium and in combination 
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with albumin and cytokeratin 19 expression defines the location of hepatic stem cells in both: 
humans and rodent models (Okabe et al., 2009; Schmelzer et al., 2007). Another marker that 
has been used for the isolation of stem cells from various tissues is Prominin-1/Cd133, which 
is a marker used for isolation of hematopoietic (Yin et al., 1997), neural (Lee et al., 2005), 
skin (Ito et al., 2006), kidney (Sagrinati et al., 2006), prostate (Richardson et al., 2004) and 
pancreatic stem cells (Oshima et al., 2007). Prominin-1 also has been demonstrated to be 
expressed in cancer stem cells of brain (Singh et al., 2003), prostate (Collins et al., 2005), 
liver (Suetsugu et al., 2006), pancreas (Hermann et al., 2007), lung (Eramo et al., 2008) and 
colon (O’Brien et al., 2007).  Although the biological role of this molecule remains largely 
speculative; it has been shown to play some role in endocytosis and iron uptake (Bourseau-
Guilmain et al., 2011). The hypothetical location of stem cells in the mature liver are the 
canals of Hering, which connect bile collecting canaliculi to the bile duct in the portal triad 
(Figure 1, A) (Theise et al., 1999). In humans, an additional quiescent stem cell subpopulation 
has been shown to exist, that resembles fetal liver stem cells and is defined by the co-
expression of albumin and cytokeratin 19 (Schmelzer et al., 2007). The quiescent liver stem 
cell population is still poorly characterized and no unique markers are known, although many 
potential marker molecules are being investigated (Okabe et al., 2009). In case of injury, these 
quiescent stem cells are able to give rise to a second pool of stem cells, which proliferate and 
expand from the biliary compartment into the parenchyma and restore the injured tissue. 
These cells are called transit-amplifying or oval cells whose known distinctive characteristic 
is the expression of some surface proteins like Tumor-associated calcium signal transducer 2 
(TROP2) or Leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and others 
(Okabe et al., 2009; Dorrell et al., 2008; Huch et al., 2013).   
 
1.2  Liver carcinogenesis 
1.2.1 Liver cancer classification and risk factors 
Liver cancer is the third most frequent cause of cancer related death worldwide. Each year 
more than half a million liver cancers are diagnosed and about 90% of them are classified as 
Hepatocellular Carcinomas (HCC) (Jelic, 2010). In adult livers three main types of malignant 
liver neoplasms are distinguished: 
1.2.2  Hepatocellular Carcinoma (HCC)  
HCC is one of the most frequent cancers worldwide. Most cases of HCC can be attributed to 
chronic liver injury resulting from viral hepatitis, alcoholism, which in some cases is 
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accompanied by fatty liver disease. These factors  together eventually lead to liver cirrhosis. 
Hepatitis B (HBV) infection accounts for 50% of all HCC cases, and most cases in children. 
Other factors that lead to elevated risk include fungal aflatoxin exposure and co-infection with 
Hepatitis C virus (HCV) (Hashem B. El-Serag, 2012). Males are at higher risk, which has 
been linked in a rodent model to higher androgen levels (Li et al., 2012). The mechanism of 
carcinogenesis is not fully understood and some evidence suggests that HCC originates from 
differentiated hepatocytes (de Boer et al., 1999), but a more recent hypothesis explains the 
cellular origin of HCC by genetically altered liver progenitor cells, that are able to generate 
tumors containing both hepatocytes and cholangiocytes (Rountree et al., 2009).  
1.2.3 Cholangiocellular Carcinoma (CCA)  
CCA is the second most common type of liver cancer that originates from the bile duct 
epithelium. Most frequently CCA develops around the seventh decade of age with a slight 
predisposition in males. The induction of cholangiocarcinogenesis needs several 
chromosomal changes, which can be triggered by prolonged inflammation of the biliary tract 
or mechanical injury. Resent evidence suggests that in some cases viral infection of 
progenitor cells might play a role in CCA initiation. In addition, several other risk factors are 
known, among which is exposure to carcinogens like thorium dioxide (Terraz and Becker, 
2005). 
1.2.4 Fibrolamellar Hepatocellular Carcinoma (FHCC) 
FHCC is a distinct form of HCC with a significantly lower frequency and mean age of onset. 
In contrast to HCC, most cases occur in non-cirrhotic livers and no specific risk factors are 
known. No sex difference in frequency has been documented (Bracatelli et al., 2005).  
1.2.5 Potential origin of liver cancer 
The origin of liver cancer still remains largely speculative. The main problem being the fact 
that the cellular hierarchy in liver tissue regeneration is not well described, therefore it is 
difficult to suggest any definitive candidate cells of origin (Yamashita and Wang, 2013). 
Some very recent publications have demonstrated unique  features of liver regeneration, 
which suggest a novel explanation for the cellular heterogeneity in liver tumors. Through 
tracing experiments it has been made evident, that differentiated liver cells are able to 
transdifferentiate into biliary epithelial cells during normal tissue regeneration (Yanger et al., 
2013). Previously this ability of hepatocytes to give rise to CCA had been demonstrated in a 
genetic mouse model (Malato et al., 2011). Furthermore, it was observed very recently, that 
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liver stem cells, lineage committed progenitors and differentiated cells are able to transform 
and produce a broad spectrum of tumors in vivo. This suggests that due to the 
transdifferentiation ability the same cell population may give rise to different kinds of tumors 
(Holczbauer et al., 2013).  
1.3 Models of liver cancer 
1.3.1 Chemical models 
Induction of HCC relies in broad terms on the administration of two chemicals: a genotoxic 
agent that introduces the genetic alterations and a promoting agent, which allows faster 
expansion of cell clones with oncogenic mutations. The administration of these chemicals 
may be combined with the removal of ¾ of the liver, which is called partial hepatectomy 
(PH). The purpose of this operation is to force the resting liver cells to divide, promoting 
thereby tumor formation. One example of a chemical model for HCC induction is 
diethylnitrosoamine/phenobarbital (DEN/PB). In this model HCC is initiated with DEN,  a 
powerful proto-oncogene whose activation relies on the activity of certain P450 cytochromes 
(Ye et al., 2012), whose expression is highest in the centrilobular hepatocytes. PB is the 
promoting agent that induces chronic injury, which in turn leads to a pre-cancerous state 
characterized by elevated cell proliferation and chronic inflammation (Yoshie et al., 1998). 
There are other chemical models, which rely on the administration of different chemicals, 
such as peroxisome proliferators, carbon tetrachloride, aflatoxin B1 and others (Heindryckx et 
al., 2009). 
1.3.2 Xenograft/allograft models 
In this type of models, the cancer cells that eventually form the tumor are injected into                                                                                                                                                   
immunodeficient mice. The cells can be injected subcutaneously or intrahepatically (Yan et 
al., 2013; Kornek et al., 2008). The intrahepatic injection model mimics due to the direct 
contact with liver tissue microenvironment the naturally occuring process of HCC tumor 
development. This allows the observation of metastasis and angiogenesis (Sun et al., 1996). 
In case of the subcutaneous injection on the other hand the tumors do not develop normally, 
because they  lack  liver tissue contact. This model is used to evaluate the tumorigenic 
potential of cell lines. In both models the outcome may vary greatly depending on the cell 
lines used (Heindryckx et al., 2009; Rountree et al., 2011).            
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1.3.3 Mouse models expressing viral transgenes 
Tumor formation is stimulated by the specific expression of different oncogenic proteins in 
liver cells of transgenic mice (Wu et al., 2001). Per se, models expressing a single viral 
protein are less effective than chemical models, but experimental evidence suggests that when 
combined with chemical tumor induction, the  expression of HCV and HBV proteins can 
promote HCC formation (Heindryckx et al., 2009). 
1.3.4 Oncogene and growth factor pathway overactivation models 
In this class of models, the artificial deregulation of cellular signalling pathways eventually 
results in highly elevated cancer risk. One example for a deregulated oncogenic pathway is 
overexpression of c-myc, which results in the acceleration of the cell cycle and eventually in 
genomic instability (Mai et al., 1996). Deregulation of the β-catenin pathway is considered to 
be an early event in hepatocarcinogenesis, which leads to the deregulation of hepatocyte 
proliferation (Harada et al., 2002). HCC induction occurs most effectively in transgenic 
models with the simultaneous deregulation of several pathways. An example of this is the 
combined overexpression of c-myc and a growth factor like Transducing Growth Factor-α 
(TGF-α) (Nicholes et al., 2002), which is as effective as the chemical DEN/PB model. β-
catenin pathway overactivation in combination with H-Ras mutation results in rapid 
formation of HCC (Harada et al., 2004). Other factors whose pathways are often deregulated 
in transgenic models are Epidermal Growth Factor (EGF) and Fibroblast Growth Factor 19 
(FGF19) (Heindryckx et al., 2009).  
1.3.5 Transgenic models with a tumor promoting environment 
One major risk factor for HCC development is liver cirrhosis and chronic liver injury. In the 
disease model systems these processes are induced by the overexpression of Platelet Derived 
Growth Factor (PDGF), which leads to liver cirrhosis and other liver pathologies (Borkham-
Kamphorst et al., 2007; Hoyle et al., 1999). In another model, the tumor promoting conditions 
are induced by the expression of a human transport-impaired Alpha-1 antitrypsin protein, 
which accumulates in the liver and eventually leads to cirrhosis and cancer. Other similar 
models include deregulation of Transducing Growth Factor-β (TGB-β) and PTEN deletion 
(Heindryckx et al., 2009). 
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2. EXPERIMENTAL PART 
2.1 Aim of the project 
The main goal of the project is to describe changes in adult stem cell markers of the liver 
during the process of tumor formation, thereby shedding light on the cell population from 
which liver tumors might arise. 
To achieve this goal I will describe the formation of  liver cancer as a constant process, 
evolving from the point of initiation to macroscopic and life threatening tumors, which 
generally do not respond to any therapy. I will investigate, which changes in liver stem cell 
populations precede the transformation of normal liver tissue into cancerous tissue and when  
these events take place. The information  about the timeframe of the events leading to cancer 
is a prerequisite for the planning of future genetic tracing experiments and eventually  might 
lead to the development of more effective means to prevent HCC at its initial stages, rather 
than dealing with consequences. 
2.2 Materials and methods 
2.2.1 Isolation of the non-parenchymal liver cell fraction 
The first step in the isolation of liver cells is the cannulation of the inferior V. Cava, followed 
by a sequential perfusion of the liver with Krebs-Ringer buffer (118 mM NaCl, 4.7 mM KCl, 
1.2 mM KH2PO4, 1.2 mM MgSO4, 4.2 mM NaHCO3, 2 mM CaCl2, 10 mM glucose) 
supplemented with 3 mM EGTA (Ethylene Glycol Tetra acetic Acid perfusion) for the first 
step, 1 mM CaCl2 and Collagenase I (0.35 mg/ml) for the second step. The livers were 
perfused with each solution for approximately 10 min and after that the gall bladder was 
removed in situ and the liver was resuspended in cold PBS and passed through a 70 µm nylon 
mesh into a 50 ml tube (~40 ml of cell suspension). This was followed by the precipitation 
and depletion of the parenchymal fraction (50 g, 2 min, 4˚C, 4 times; 3 times 100 g, 1 min, 
4˚C). After the parenchymal cells were depleted, non-parenchymal fraction was collected at 
200 g, 10 min, 4˚C (volume ≤ 20 ml). For lysis of erythrocytes the final cell pellet was 
resuspended in 1 ml of BD Pharm Lyse™ Lysing Buffer (1 x) and incubated on ice for 15 
min. After the incubation the suspension was diluted with cold PBS to 5 ml and centrifugated 
at 200 g for 5 min, 4˚C. Pellet was collected, resuspended in 90 µl of Miltenyi buffer (2 mM 
EDTA, 0.5% BSA in PBS) and 10 µl of Miltenyi Cd45 micro beads were added for leukocyte 
depletion. The cell suspension was incubated on ice for 15 min, which was followed by the 
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application of the cell suspension to a calibrated column. The flow fraction was collected. The 
depletion procedure was performed according to the manufacturer’s recommendations. 
2.2.2 FACS analysis  
Prior to antibody staining the cells were suspended in 1% BSA/PBS solution and incubated 
for 1 h on ice. The cells were incubated in a 1:100 primary antibody dilution for 1 h, which 
was followed by 3 x 1 ml PBS wash. Analysis was performed on FACS Calibur. 
2.2.3 Immunofluorescence staining and sample preparation 
Fresh liver tissue was embedded in TISSUE -TEK® O.C.T. COMPOUND and shock-frozen 
in liquid nitrogen. Staining was performed on 6 µm thick tissue slices. Each slice was fixed 
with a 4% paraformaldehyde (PFA) solution in phosphate buffer saline (PBS) for 10 min 
followed by 2 x wash, 5 min each. Tissue samples were permeabilized (if required) with a 
0.1% Triton X-100/PBS solution for 5 min at room temperature (RT), which was followed by 
a single wash and blocking with 4% goat serum in PBS for 1 h, RT. After blocking, the tissue 
samples were incubated with a dilution of the primary antibody (100 µl/sample) in the 
blocking solution (1 h, RT) and washed 3 times with PBS (5 min per wash). The secondary 
antibody was diluted in the blocking solution 1:500 and applied to the tissue samples (100 
µl/sample) for 30 min, RT which was followed by 3 x wash (5 min). Mounting was performed 
with DAKO Fluorescent Mounting Medium (30 µl/sample). 
2.2.4 Antibodies and dilutions: 
Santa Cruz Biotechnology, INC. goat anti-mouse HNF-4α (IF: 1:100); Epitomics. rabbit anti-
mouse Cytokeratin 19 (IF: 1:3000); eBioscience. rat anti-mouse Cd133PE (FACS 1:100; IF 
1:20); eBioscience. rat anti-mouse Cd166PE (FACS 1:100; IF 1:100); eBioscience. rat anti-
mouse Cd24eFluor® 450 (FACS 1:100; IF 1:100); eBioscience. rat anti-mouse Cd45 PE 
(FACS 1:250; IF 1:250); Biolegend. Purified. rat anti-mouse Cd325 (Epcam) (FACS 1:100; 
IF 1:100); BD Pharmigen. rat anti-human Cd49f-PeCy5 (IF 1:20). 
2.2.5 Haematoxylin and eosin staining and sample preparation 
Tissue samples were fixed overnight in a 4% PFA/PBS solution and dehydrated with a 
alcohol gradient ranging from 70-100 vol. over a period of four days, which was followed by 
incubation in xylene (2 x 1 h) and incubation in molten paraffin for embedding (first paraffin 
2 h, second overnight). Staining was performed on up to 7 µm thick tissue slices. The tissue 
slices were dewaxed by dissolving the paraffin in xylene (2 x 15 min) and rehydrated with an 
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alcohol gradient starting with 100 and ending with destilled water. First the samples were 
stained with Mayer’s haematoxylin for 5 min and rinsed in cool tab water (~1 sec) and 
incubated in Scott's tap water substitute (0.238M NaHCO3; 0,813M MgSO4 in MQ water) for 
up to 5 min. Counter staining with 1% eosin for 1 min and transfer into 70% alcohol for 1 min 
(maximum). Mounting was performed with a xylene based medium after dehydration. 
 
2.2.6 Experimental design 
Liver cancer was initiated in a group of male mice with an intraperitoneal injection of DEN in 
PBS (50 µg/g). Initiation was followed by the administration of PB dissolved in saline (0.5 
g/l), until sacrifice. During  the experiment, tissue and RNA samples were collected from 
several time points (Figure 3). 
 
Figure 3. Scheme of the study.  In the course of the experiment several kinds of samples were collected for 
analysis of tissue morphology (paraffin/cryo block embedded tissue), cellular composition (FACS) and gene 
expression (total RNA for qPCR) (5, 8, 13, 25, 40 weeks).  
 
 
15 
 
 
3. RESULTS 
3.1 Histochemical analysis of liver tissue 
The experimental group (30 mice) received an intraperitoneal injection of DEN in PBS. PB 
promotion started one week after initiation. The control group (15 mice) was injected with 
sterile PBS (Figure 5, a). Samples were collected 5, 8, 13, 25 and 40 weeks after initiation 
with DEN. From the 5
th
 week after initiation signs of inflammation were evident in the form 
of  basophilic infiltrates (Figure 4). 
 
Figure 4.  Haematoxylin-stained liver paraffin sections (5
th
 week). a) Basophilic infiltrates in a DEN initiated 
(arrows) liver sample. b) Infiltrates were absent in the PBS-treated control  samples. 
The majority of these infiltrates disappear by eight week after the initiation, which indicates 
the end of the acute phase. At the 25
th
  to the 40
th
  week haematoxylin and eosin staining of 
the liver samples showed severe intoxication (caused by prolonged phenobarbital ingestion), 
which is evident from the weak eosinophilic staining of the cytoplasm (Figure 5, b) and  
nuclei of hepatocytes start to exhibit a greater variation in size. 
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Figure 5. Haematoxylin eosin staining of liver tissue paraffin sections (arrows indicate central veins). a) 
Tissue sample from a control mouse (injected with PBS); b) liver tissue 25
th
 week after initiation (DEN/PB 
treated), lack of staining indicates severe intoxication as a result of chronic PB ingestion. 
All mice from the 40
th
 week time point had macroscopic liver tumors, which by means of 
histological analysis (performed by Ivar Blank, an animal pathologist from the Estonian 
University of Life Sciences, Institute of Veterinary Medicine and Animal Sciences) were identified 
as hepatocellular carcinomas (HCC) (Figure 6).   
 
Figure 6. Haematoxylin/eosin staining of cryosections obtained from different macroscopic tumors. a) 
Tumor with liposis, arrows indicate fat incrustations, b) tumor containing leucocyte infiltrates (indicated by 
arrows), c) 1. Tissue compression caused by tumor growth, 2. HCC, d) tumor containing nuclear fragments, 
which indicates necrosis.  
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Multifocal HCC is defined by the presence of several foci composed of malignant 
morphology exhibiting hepatocytes. The malignant cells have and unusually small amount of 
cytoplasm and relatively big nuclei. In our model we did not observe this kind of HCC within 
macroscopic tumors, but only in one general liver tissue sample (Figure 7. a, b). 
 
Figure 7. Hepatocellular carcinomas, paraffin section haematoxylin/eosin staining. Mouse liver sample 
collected from the 40
th
 week time point (DEN and PB treated) did not contain macroscopic tumors. a) arrows 
indicate different HCC foci, b) HCC focus.  
Histological analysis of the lungs showed the presence of neoplasms which, based on the cell 
morphology, were identified as liver cancer metastasis. The metastasized cell morphology 
resembles the liver cancer cells (Figure 8, a and b) Immunohistochemical staining of the 
metastasis demonstrated the absence of the hepatocyte specific marker HNF4α (data not 
shown) (Figure 8). 
 
Figure 8. Metastasis to the lung. a) Cell morphology resembles liver cells. b) The metastasized cells formed 
clearly visible nodes on the surface of the lungs.  
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3.2 Analysis of changes in liver SC markers 
3.2.1 Immunofluorescence analysis of stem cells markers (IF) 
To describe changes in distribution of stem cell markers in the liver during the process of 
tumor formation I stained tissue samples from week 5 to 40 for the following stem cell 
markers: Epcam/Cd 326, Alcam/Cd 166), Prominin-1/Cd 133 (SC marker), Cd 24. In addition 
I analysed the samples for cytokeratin 19 (ck19), a biliary marker; Ki67, a proliferation 
marker and for Cd 45, a marker for hematopoietic cells. 
Ki67 is a cell proliferation marker and is expressed in the non-injured liver in a small number 
of cells. Five weeks after the first DEN injection Ki67 expression is elevated compared to the 
PBS control (especially around K19-positive bile ducts, indicating injury in the biliary 
compartment; Figure 9, a - insert) and normalizes around the 13 week time point, with a small 
amount of positive cells dispersed over the sample (Figure 9, c).
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Figure 9.  Cell proliferation increases after DEN injection. a) 5 weeks after (insert: scale bar 125µm) and b) 
eight weeks after intraperitoneal injection of  the DEN/PB treatment (PBS for control mice,) I observed 
increased Ki67 levels in proximity of the ck19
+ 
bile ducts (insert). c) By the 13
th
 week, Ki67 levels in the 
initiated mouse liver samples  are equal to the control samples. d) On the 25
th
 week areas with increased levels of 
proliferation emerge again in the DEN/PB treated liver samples, e) which expand until the 40
th
 week. 
A second wave of proliferation occurred around the 25
th
 week time point and continued until 
the 40
th
 week (Figure 9, d and e). 
Between week 13 and 25 ALCAM
+
 positive cells start expanding, producing large ALCAM 
positive areas. This is supported by the double staining with Ki67. (Figure 10, a and b).  
At the 25 weeks an increase in overall Ki67 expression was evident, areas with increased 
proliferation started appearing, most of which were positive for ALCAM. This indicates that 
tumor formation started between the 13
th
 and 25
th
 week after initiation (Figure 9: c, d; 10).  
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Figure 10. Proliferating Cd166
+
 cells start to form foci from the 13
th
 week. a) Starting from the 13
th
  week I 
observed the appearance of Cd166 positive foci, with an  increased level of Ki67 and Cd166. Arrows indicate 
different  levels of cd166 expression observed in the liver parenchyma of DEN/ PB treated mice. b) Proliferating 
focus with increased Cd166 expression. By the 25
th
 week these foci formed large areas (microscopic tumors). 
By the 40
th
 week macroscopic tumors developed, most of which show a high level of 
ALCAM expression and proliferative activity (Figure 11). The ALCAM-positive areas found 
at the 25
th
 week time point resemble the ALCAM/Ki67 staining pattern found in macroscopic 
tumors suggesting that the former present microscopic tumors formed in the liver. 
 
Figure 11. Tumor tissue immunofluorescence. Macroscopic tumors show elevated levels of Cd166 expression, 
which coincides with high areas containing cells with increased proliferation (Ki67).  
In healthy liver tissue SC markers always co-localize with the biliary marker ck19 (Figure 12: 
a, b, c). 
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Figure 12. Distribution of SC markers in normal liver tissue. The expression level of a selection of known 
liver stem cell markers is highest in the biliary compartment. In  uninjured tissue these markers are co-expressed 
with ck19 in the bile ducts. a) Cd 166 expression is highest in the biliary compartment, weak signal is present in 
the parenchyma, b) Epcam is localized exclusively in the biliary compartment, c) Cd133 is also expressed only 
in the biliary compartment.  
However, in both tumor and liver tissue of DEN/PB-treated mice I observed the appearance of 
a novel cell phenotype that is characterised by the ck19 expression and the loss of stem cell 
markers (Figure 13, 14). 
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Figure 13. Distribution of stem cell markers in liver tissue samples at the 40
th
 week time point. On the 40
th
 
week I observed the appearance of a novel ck19 single positive cell phenotype in non-cancerous liver tissue of 
DEN/PB-treated mice, a) ck19
+
/Cd166
-
, b) ck19
+
/Epcam
-
, c) ck19
+
/Cd133
-
. 
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Figure 14. Distribution of SC markers in cancer tissue. a) In tumor samples ck19
+
/Cd166
-
 single positive 
cells appear. Most of the Cd166
+
 cells are ck19
-
. b) Loss of Epcam by ck19
+
 cells appears to be less extensive, 
but some ck19
+
/Epcam
-
 cells can be found.  c) ck19
+
/Cd133
-
 cell population.  
3.2.2 FACS analysis of liver SC markers 
To study the quantitative changes in the liver stem cell marker expression I subjected the non-
parenchymal fraction of liver cells, obtained at various time points during the experiment to 
FACS analysis of selected liver SC markers (Figure 15).  
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Figure 15. Summary of the FACS analysis of the non-parenchymal cell fraction. FACS analysis describes 
changes in the SC containing non-parenchymal fraction. Significant increase in stem cell markers is evident by 
the 40
th
 week after DEN injection and start of PB promotion. a) After the DEN injection (5w) percentage of 
Epcam
+
 cells decreased, and  it has doubled compared to the control group, by the 40
th
 week time point. b) and c) 
show a similar tendency: substantial increase in Cd166
+
 and Cd133
+ 
cells after the DEN injection with a 
threefold increase at the end of the experiment (40w). d) Value of the Y axis. 
The expression level of all studied SC markers (EPCAM, ALCAM, Prominin-1) abruptly 
changes after initiation (DEN injection) compared to the control group, which indicates the 
damage of the biliary three (Figure 15).  
At this initial stage (5 weeks) a significant increase in Cd133 and Cd166 can be observed, 
which indicates an active involvement of stem cells in the regenerative process and at the 
same time a twofold decrease in Epcam is evident (Figure 15). Regeneration after the acute 
injury (DEN injection) appears to be completed in the timespan from 13 to 25 weeks, since 
FACS data shows the normalization of the studied SC markers by the 25
th
 week (DEN/PBS 
ration ≈ 1) (Figure 15, 25w).  
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DISCUSSION 
In this study I aimed to shed light on the cellular events, which lead to the appearance of liver 
cancer. For this purpose I induced chemically liver cancers in male CBA mice and described 
the expression pattern of selected liver SC markers during this process. 
Based on the quantitative data from FACS analysis the tumor formation process can be 
divided into two phases: the first phase is characterised by the regenerative response caused 
by the injury from the  DEN injection. During this phase I noticed the increased inflammatory 
response and cell proliferation, especially in the peribiliary region (Figure 9; 10). The acute 
injury is followed by the second phase, where I identified the changes in cellular composition 
of the liver caused by immortalization of cells and tumor growth discussed below. 
Immediately after the DEN injection and start of PB (5 weeks) promotion I observed a 
substantial decrease in Epcam
+ 
cells, which indicates the damage of the biliary tree. First 
evidence of expanding cancer cells I observed at the 13 week time point when the 
regeneration process was over, and by the 25 week time point all DEN/PB treated mice had 
developed microscopic liver tumors (Figure 10). Therefore I conclude that in this model the 
oncogenic transformation generally occurs between the 13
th
 and 25
th
 week and the most 
significant cancer related changes in marker frequency must take place at this time. Those 
stem cell markers, which are expressed solely in the biliary compartment (Epcam, Cd133) 
displayed significant changes by the 40
th
 week with tumor/tissue signal ratio greater than one 
(Figure 15). Immunofluorescence analysis of macroscopic tumors showed the prevalence of 
Cd166
+
 cells, which were ck19 negative (Figure 13). This indicates, that most of the 
macroscopic tumors probably originate from the immortalization of unipotent hepatocyte 
progenitor cells, which formed microscopic tumors as early as 13 weeks after starting the 
treatment (Figure 10; 11).  As mentioned above, a possible explanation lies in the selective 
carcinogenicity of DEN (Ye et al., 2012).  The DEN metabolizing cytochrome P450 2E1 
together with other cytochromes is considered a hepatocyte lineage marker (Golding et al., 
1995), which means that it is absent in bipotent or unipotent biliary lineage liver stem cells.  I 
speculate that these are hepatic progenitors that represent the first step in the differentiation 
cascade of hepatic SC, which start to express the enzymes, which metabolize DEN to a 
carcinogenic product. Such cells might be hit preferentially by DEN and serve as cells of 
origin for HCC. As discussed above even differentiated cells can be the cell of origin for HCC 
(Holczbauer et al., 2013). The use of genetically engineered mice to trace the different SC and 
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progenitor populations in liver HCC formation would give a definitive answer to this 
question.   
A potential HCC metastasis to the lungs was observed at the 40 week time point. The exact 
origin of the cells remains speculative since the metastasized cells did not express hepatic 
marker HNF4α. However, this does not exclude their hepatic origin, since recent reports 
show, that HNF4α deletions might be one of the factors responsible for HCC promotion 
(Walesky et al., 2013).  
Another interesting observation is that in parallel to cancer progression within the liver I saw 
the loss of stem cell markers in the biliary compartment. One possible explanation would be 
that the loss of adherence molecules would facilitate the detachment of cells from their niche, 
which  is a prerequisite for metastasizing and epithelial-mesenchymal transition. The latter is 
considered an important step in cancer progression (Brabletz et al., 2001;Thiery et al., 2009). 
The origin of multifocal HCC (Figure 7) remains unclear, since I did not find any markers 
specific for this type of HCC. At the same time the metastasized cells observed in the lungs 
show close morphological resemblance to the cells comprising these HCC foci. 
I observed also the presence of  ck19-expressing cells in the DEN/PB
 
treated group at the 40
th
 
week, which were devoid of other SC/biliary markers. The appearance of such cells is 
probably the result of chronic intoxication with PB, since they were present both in non-
cancerous tissue as well as in tumor samples.  
Taken together, the changes in SC/biliary marker expression during the initial phase (~first 13 
weeks) occur most likely due to the presence of the regenerative processes in response to the 
acute injury imposed by DEN injection. The results suggest that the increase in the number of 
cells expressing Epcam and Cd133 that was observed after the 25 week time point is related 
to tumor growth, since after this time point I observed the appearance of macroscopic tumors. 
I also found that the changes arising in the SC compartment in the DEN/PB liver cancer 
model are too modest to be detected using immunofluorescence analysis, but are readily 
identified using FACS analysis (Figure 15). A further comparison of marker expression at the 
mRNA level in tumors and bulk tissue samples is needed to validate my observations.  
The research addressing the events preceding the onset of cancer expands our knowledge 
about liver cancer formation and is important for the development of any new treatment or 
preventive approaches of liver cancer path way for the identification of novel  drug targets for 
HCC treatment. 
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SUMMARY 
Hepatocellular carcinoma is the most common form of malignant liver cancer and the third 
most common cause of cancer related mortality worldwide. The main reason for this is the 
lack of effective treatment approaches. 
Transformed adult stem cells in the liver, or cancer stem cells appear to be the cause of cancer 
spread and relapse in some cases. Nevertheless, the changes that precede the malignant 
transformation of liver cells are largely unknown, and there is very little information about the 
changes occurring before the onset of tumor growth. The goal of this study was to describe 
the appearance of liver cancer as a constant process,  evolving from the point of initiation to 
the terminal (lethal) stage, rather than dealing only with advanced tumors.  
Therefore, I used a chemical model of liver cancer, which relies on the administration of a the 
carcinogen diethylnitrosamine (DEN), and phenobarbital (PB), to induce liver cancer in a 
group of male CBA mice. The control group consisted of non-initiated CBA mice. Liver 
samples from both groups were collected 5, 8, 12, 25 and 40 weeks after administration of 
DEN.   
Analysis revealed increased inflammatory response and proliferation during the first 13 weeks 
after initiation, caused by acute injury. In the timespan from the 13
th
 to 25
th
 weeks I observed 
the appearance of Cd166
+
 expressing microtumors.  
By the 40
th
 week all DEN/PB treated mice developed macroscopic tumors, which were 
classified as hepatocellular carcinomas (HCC). The majority of HCC tumors showed an 
increased expression level of Cd166. I also observed increase in the cancer-/stem cell markers 
Cd133 and Epcam, which appears to be related to tumor growth.  
This approach allowed us to build a timeframe of events, which accompany the transition 
from normal liver tissue to cancer and how liver stem cells engage in this process. 
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REGULATION OF ADULT STEM CELLS IN MOUSE LIVER 
TUMORIGENESIS 
Denis Belitškin 
RESÜMEE 
Käesoleva magistritöö eesmärgiks oli uurida maksa täiskasvanud tüvirakkude osalust maksa 
kasvajate tekkeprotsessis. Selleks kasutati DEN/PB manustamisel põhinevat keemilist maksa 
kasvajate indutseerimise mudelit. 
Kirjanduse ülevaates anti kokkuvõte maksa tüvirakkudest ja nende rollist maksa koe 
taastamises erinevates olukordades. Samuti tutvustati ka kasvajatüvirakke ja nende seost 
täiskasvanud tüvirakkude ja vähiga. Lisaks sellele kirjeldati peamisi kasutuses olevaid maksa 
vähi mudeleid. 
Töö raames indutseeriti isastel CBA katsehiirtel maksa kasvajate teke, mille järel võeti 
proovid maksa koest 5, 8, 13, 25 ja 40 nädalat  pärast kasvajate initsieerimist. Kontrollgrupi 
moodustasid sama vanad normaalsed isased CBA hiired. Leiti, et alates 13. nädalast algab 
Cd166 ekspresseerivate rakkude paljunemine ja 25. nädalaks on moodustunud 
mikroskoopilised kasvajad, mis on eristatavad  kõrgenenud Cd166 ekspressioonitaseme tõttu. 
40. nädalaks arenesid kõigil DEN/PB initsieeritud hiirtel maksarakulised kasvajad. Edasine 
analüüs näitas, et Cd166 ekspressioonitase makroskoopilistes kasvajates oli oluliselt kõrgem 
kui normaalse koe proovides, millest võib järeldada, et nende tuumorite formeerumine algas 
umbes 13 nädalat  pärast initsieerimist. Kuna need rakud ei ekspresseerinud sapijuha 
markereid, võib spekuleerida, et need on suure tõenäosusega immortaliseerunud 
parenhümaalse hepatotsüüdi järeltulijad. Lisaks sellele leidsime ka teiste tüviraku ja 
kasvajatüviraku markerite tõusu (Epcam, Cd133), mille olemust tuleb selgitada edasiste 
uuringute käigus. 
Antud katse ülesehitus erineb paljudest teistest, kus vaadeldakse maksa vähki kui produkti. 
Antud projektis rakendatud lähenemine võimaldab kirjeldada vähi tekkele eelnevaid 
sündmusi, mis omakorda võib viia uute maksa vähi teraapia ja ennetusstrateegiate 
väljatöötamisele. 
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